Epitalon: the evidence, and why it is not Epithalamin

Epitalon is not Epithalamin, and FDA put that in writing

The dispute has a paper trail: two parties asked FDA to allow Epitalon in pharmacy compounding, and told the agency that epithalamin was another common name for the same thing. FDA disagreed on the record. Footnote 6 of its May 2026 evaluation reads that FDA "considers epitalon and epithalamin as different substances", describes epithalamin as a polypeptide complex extracted from the pineal gland, and describes Epitalon as a tetrapeptide synthesized from the study of that complex's amino acid content.

The registry line that settles it for FDA: the same footnote records that epithalamin is not listed as a synonym for Epitalon under unique ingredient identifier O65P17785G in FDA's Global Substance Registration System. Elsewhere the document notes that seven of the articles submitted with the nominations discussed epithalamin rather than the tetrapeptide.

Why the mix-up keeps spreading anyway: the chemical registries do not agree with the drug registry. Retrieved on 4 August 2026, the PubChem entry for CID 219042 carries 39 synonyms, and two of them are Epithalamin and Epithalamine. So a reader checking the name in the public chemical database is told the two words point at one compound, while the regulator that has to decide what may be put into a person says they do not.

The practical consequence for a vial: identity is not purity, and a certificate reporting a high percentage says nothing about which of the two substances is being described. That distinction is what a purity figure does not establish, and it is doing more work on this compound than on almost any other.

The first four rows carry the longevity numbers: the mortality ratios, the 28 percent and the fifteen-year follow-up all sit in rows whose second column says Epithalamin. Attaching those rows to the tetrapeptide produces a sentence about an extract from a gland pinned to a synthetic four-amino-acid chain that no long trial has ever tested.

Every human study put it somewhere other than under the skin

FDA counted them: after conducting a literature search, three studies were found in which Epitalon was administered to humans. Two gave it sublingually to shift workers, one to look at circadian gene expression and one at the excretion of a melatonin metabolite. The third injected it parabulbarly, beside the eyeball, in congenital retinitis pigmentosa.

What the nominations asked for instead: subcutaneous injection, at 10 mg/mL and at 3000 mcg/mL. Those two strengths sound far apart and are not: 3000 micrograms is 3 milligrams, so the proposed products differ by a factor of about three, not a thousand. FDA notes separately that limited water solubility may make a 3 mg/mL injection difficult to compound with water as the solvent.

Why the route is the whole point here: a peptide placed under the tongue, a peptide deposited in the tissue behind the eye and a peptide pushed into subcutaneous fat are three different exposures, and the differences between the routes a study actually used do not wash out because the molecule is the same. Nothing in the human record was delivered by the route the nominations proposed.

The sentence FDA wrote about all of it: "there are no clinical data to support the safety of epitalon (free base) or epitalon acetate when used in humans." The agency adds that it identified no human safety data for the proposed subcutaneous route in particular, and flags immunogenicity risk from peptide aggregates and unspecified impurities.

One regulatory footnote worth keeping: Epitalon did hold an orphan drug designation for retinitis pigmentosa, granted on 2 September 2010. FDA's evaluation records that the designation was withdrawn or revoked on 6 January 2016. A designation is a development incentive rather than a finding that something works, and this one is no longer live either way.

The telomere result is real, and it was made in a dish

The original finding, 2003: adding the peptide to telomerase-negative human fetal fibroblast culture induced expression of the telomerase catalytic subunit, enzyme activity, and telomere elongation. The follow-up in 2004 pushed primary fetal lung fibroblasts that had stopped dividing at passage 34 to 44 passages, ten extra divisions. Both are cell-culture experiments, and both come from the St. Petersburg institute that developed the compound.

The independent replication, 2025: a group at Brunel University London, with a co-author at Royal Brompton Hospital, treated two breast cancer lines and normal epithelial and fibroblast cells and reported dose-dependent telomere extension in the normal cells through hTERT upregulation and telomerase activity, plus telomere extension in the cancer cells through alternative lengthening of telomeres, which was specific to the cancer cells. It carries weight because the 2003 and 2004 telomere papers came from the institute that developed the compound, and this group did not.

What the treatment actually was: concentrations of 0.1 to 1 microgram per milliliter of culture medium for four days in the cancer lines, and 1 microgram per milliliter for three weeks in the normal lines. That is a concentration in a dish. It has no arithmetic relationship to an amount injected into a person, and no paper in this record supplies the bridge between the two.

The correction, and what it is not: on 15 November 2025 the journal published a Correction stating that "the wrong figures appeared in Figs. 1, 2 and 3", with corrected versions supplied. Those are the three primary data figures. It is a figure correction, the article is not marked retracted, and the authors disclosed it themselves. Reporting it as a retraction would be wrong; leaving it out would be worse.

The rest of the 2025 work, same category: a group at Chieti-Pescara, writing with three co-authors from the St. Petersburg institute including Khavinson himself, reported faster wound closure in a human retinal pigment epithelial cell line modeling diabetic retinopathy, and a Korean group reported telomerase activation improving bovine oocyte maturation and post-thaw embryo development. One is a cell line, one is cattle gametes, and the wound-healing paper's own conclusion states that more mechanistic investigation is needed to confirm the peptide's benefits and safety, which is the originating institute asking for the work from its own byline.

What is Epitalon?

A four-amino-acid peptide, alanine to glutamic acid to aspartic acid to glycine, written Ala-Glu-Asp-Gly and abbreviated AEDG in the literature. PubChem holds it as CID 219042 with molecular formula C14H22N4O9 and a molecular weight of 390.35, and FDA's substance registry assigns it the identifier O65P17785G. The 2025 review in the International Journal of Molecular Sciences describes it as designed from the amino acid composition of the pineal extract, which is why the two names travel together.

What it is supplied as: FDA describes the free base as a white to off-white lyophilized powder with limited reliable aqueous solubility data in the literature. The rest of what that word implies about a vial is on the page about what freeze-drying does and does not fix.

What is the difference between Epitalon and Epithalon?

Nothing. They are two spellings of the same tetrapeptide, and Epithalone is a third. FDA's evaluation states plainly that Epitalon "is also known as epithalon and/or by its amino acid components", and the PubChem record for CID 219042 carries all three spellings in its synonym list. The 2003 and 2004 cell-culture papers are titled with Epithalon while the 2002 eye trial is titled with Epitalon, and both describe Ala-Glu-Asp-Gly.

The name that does mean something else: Epithalamin, one syllable longer, which is the extract rather than the synthetic peptide. That single syllable is carrying most of the confusion around this compound, and it is the reason this page opens with it.

Is Epitalon an approved drug anywhere we could check?

Not in the United States. FDA's evaluation records that there is no applicable United States Pharmacopeia or National Formulary drug substance monograph for either form, and that neither is a component of an FDA-approved drug. The list it was being considered for, the 503A Bulks List, is permission for pharmacies to compound with a substance, which is a lower bar than approval and one FDA staff proposed it should not clear.

Outside the United States: the nomination paperwork reproduced inside the FDA document answers the question about recognition in foreign pharmacopeias with two words, Russian Pharmacopoeia. That is the nominator's own answer on a form, not an FDA verification of it, and this page treats it as what it is.

What we could not check: the European position. Our requests to the European Medicines Agency search endpoint were refused before any result was returned, so no claim about European status appears anywhere on this page in either direction.

Has Epitalon been tested in people?

Yes, three times by FDA's count, and never by the subcutaneous route the nominations proposed. The eye study is indexed by PubMed as a controlled clinical trial and reports a positive clinical effect in 90 percent of cases, but its abstract states no number of patients, no schedule and no comparison group detail. The 2025 review fills those in: 162 patients aged 18 to 72, 5.0 micrograms per eye injected parabulbarly for ten consecutive days, a control group given the conventional treatments of 2002, and no side effects reported in the treated group. Those details come from the review, not from the trial's own abstract, and this page reports them at that remove rather than promoting them to primary findings.

The sublingual work: the Russian-language study reports a 1.7 fold increase in urinary 6-sulfatoxymelatonin in middle-aged people whose level was low to begin with, hyperexpression of the Clock and Csnk1e genes in leukocytes normalized by a factor of 1.9 to 2.1, and low Cry2 expression in blood lymphocytes doubled. FDA describes the same work as randomized and placebo-controlled in 75 healthy women aged 40 to 50 who mostly worked nights. FDA counts that material as two of its three studies, citing Ivko et al. 2021 for the melatonin metabolite and a separate Khavinson, Linkova and Ivko 2021 paper in World Heart J for the clock genes in immune cells. Only the first is indexed in PubMed, and its abstract carries both sets of results, which is why one record below covers both and this page says so rather than quietly counting two.

The honest summary of that: one small trial in an eye disease, and two small sublingual studies in night-shift workers reporting a melatonin metabolite and clock-gene expression. That is the entire human record for the tetrapeptide, and none of it measured aging or lifespan at all.

Does Epitalon lengthen telomeres?

In cultured human cells, yes, and that has now been shown by a group with no connection to the originating institute. In a person, unknown: no study in this record measured telomere length in a living human being who took it. The gap between those two sentences is the entire distance between a mechanism and an outcome, and this compound has never crossed it in a published human study.

Where the review lands: the 2025 International Journal of Molecular Sciences overview states that the mechanism remains unverified, that safety information is missing, and that toxicity studies are needed before the peptide could be approved as an active pharmaceutical ingredient. That is the most favorable recent survey of this compound, by authors whose own title calls its properties promising.

Why does a telomere peptide raise a cancer question?

Because the mechanism FDA found in the marketing is the same mechanism it names as the hazard. Its evaluation records wellness clinics promoting Epitalon as an anti-aging agent, some calling it "the fountain of youth", on the stated grounds that it increases telomerase production. Later in the same document, in its nonclinical safety section, FDA states that Epitalon "has the potential to be carcinogenic" and gives its reason directly: it has been shown to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with increased risk for cancer.

What that is and is not: a mechanistic concern that FDA says the animal work is too limited to settle. The agency lists the limitations it found in those studies, a fixed dose, female mice only, and short exposure, and concludes they do not adequately inform either the genotoxic or the carcinogenic potential. Written as reassurance that would be dishonest. Written as a demonstrated cancer risk it would be equally wrong.

The detail that makes it concrete: in the 2025 replication, the alternative lengthening pathway switched on in the two cancer lines and barely moved in the normal ones. The authors present that as evidence the normal-cell effect runs through telomerase. It is also, read the other way, a cell-culture observation that cancer cells respond to this peptide.

What did the FDA review conclude?

FDA evaluated Epitalon free base and Epitalon acetate for the 503A Bulks List, the list of substances that may be used in pharmacy compounding, and published a 64-page briefing document dated 12 May 2026 for the Pharmacy Compounding Advisory Committee meeting of 23 to 24 July 2026. The agenda lists exactly one use evaluated for this substance: insomnia. The other proposed uses were not evaluated, because the nominations lacked enough information to assess them.

The procedural oddity: both nominations were withdrawn, and FDA evaluated the substance on its own initiative anyway. So the document exists without a sponsor defending it, which is unusual, and it is the reason a compound with almost no Western literature has a 64-page federal review attached to it.

What the document does not tell us: what the committee voted. As of 4 August 2026 no minutes and no voting record appear on FDA's meeting materials page for this meeting, so any tally circulating for it cannot be checked against a primary document and does not appear on this page.

A quality note buried in the same review: FDA looked at a publicly posted certificate of analysis for this substance and found no information about impurity limits or impurity testing results on it, which it treats as part of the immunogenicity concern. It is the gap described on the page about a certificate that reports a purity number and little else, found here by a regulator looking at a document for this specific substance.

How big is the Epitalon literature?

Small, and not empty. PubMed returns 132 records for the term epitalon, across all fields, retrieved on 4 August 2026; the alternate spelling epithalon returns 126 and the two sets overlap heavily. Narrowing the first search to human subjects with the query epitalon AND humans[mesh] returns 36, and that subset still contains the Epithalamin trials, because the two names sit side by side in the same papers.

The registry is emptier: ClinicalTrials.gov, queried the same day, returns zero studies for epitalon and zero for epithalon. The same query shape returns 757 for semaglutide, which is what a compound with a trial program looks like in that database. Zero is not proof that no trial has ever run anywhere; it is proof that none is registered there.

Where the literature lives: the reference list below makes the shape visible. Of the thirteen papers cited here, nine come from the St. Petersburg institute or its collaborators, and five of those nine sit in one journal, Bulletin of Experimental Biology and Medicine. That concentration is not a reason to discard the work, and this page cites all nine. It is the reason a single result from an unconnected laboratory moves the picture more than another paper from the same source would.

The six gaps this record leaves open

Written as gaps, because that is what they are:

• Anything about the subcutaneous route. No human study in this record used it, and FDA states it found no safety data for it.
• Whether the telomere effect happens in a person. Every telomere measurement here was taken from cells in a flask.
• Pharmacokinetics. The 2025 review carries no half-life, no bioavailability and no exposure data, and neither does anything else in this file.
• The carcinogenicity question. FDA states the mechanism raises it and the animal studies are too limited in scope and duration to answer it.
• Whether the extract results transfer. The tetrapeptide was designed from the extract's composition, which is a chemical relationship, not evidence that it does the same thing in a body.
• What the advisory committee decided. The staff recommendation is public. The outcome of the meeting, on the record, is not yet.

How this page is sourced

What was opened and read in full: the 64-page FDA briefing document, retrieved as a PDF, the FDA advisory committee agenda page, twelve PubMed records with their abstracts, the full text of the published Correction, and the PubChem compound record. Every PubMed identifier and every DOI on this page was resolved on 4 August 2026 before it was printed.

The one number this page refuses to print: a committee vote tally that several secondary write-ups report. FDA has published no minutes and no voting record for the meeting, so nothing primary supports it, and a number with no document behind it does not go on this site whatever its source.

One correction to a claim we checked and could not confirm: it is sometimes said that PubChem's synonym list omits epithalamin, which would make the chemical registry agree with FDA. It does not. The retrieved synonym list for CID 219042 includes both Epithalamin and Epithalamine, and the page above says so rather than repeating the tidier version.

Sixteen sources: two FDA documents, thirteen indexed papers with a PubMed identifier and, where the publisher issued one, a DOI, and one chemical registry record.

Who checked it: the reviewer policy behind this page, and the citation standard every identifier above was resolved against, are set out on the methodology page.

Last reviewed: 4 August 2026.

1. 1

   U.S. Food and Drug Administration. Evaluation of Epitalon-Related Bulk Drug Substances (Epitalon (Free Base) and Epitalon Acetate) for Inclusion on the 503A Bulk Drug Substances List. Briefing document for the Pharmacy Compounding Advisory Committee meeting of 23 to 24 July 2026, memorandum dated 12 May 2026, docket FDA-2025-N-6895. 64 pages. Retrieved 4 August 2026. fda.gov, briefing document 193345.

2. 2

   U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee, meeting notice and agenda, including the table of uses evaluated. Retrieved 4 August 2026. fda.gov, advisory committee meeting page.

3. 3

   Araj SK, Brzezik J, Madra-Gackowska K, Szeleszczuk L. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025;26(6):2691. Review. doi:10.3390/ijms26062691. PMID 40141333.

4. 4

   Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. Cell culture, not a human study. doi:10.1023/a:1025493705728. PMID 12937682.

5. 5

   Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503-506. Cell culture, not a human study. doi:10.1023/b:bebm.0000038164.49947.8c. PMID 15455129.

6. 6

   Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. Brunel University London and Royal Brompton Hospital. Cell culture, not a human study. doi:10.1007/s10522-025-10315-x. PMID 40908429.

7. 7

   Al-Dulaimi S, Thomas R, Matta S, Roberts T. Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;27(1):1, published 15 November 2025. Published erratum correcting Figures 1, 2 and 3; the article is not retracted. doi:10.1007/s10522-025-10326-8. PMID 41240216.

8. 8

   Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-368. Indexed by PubMed as a controlled clinical trial; parabulbar route. This journal issued no DOI for the article. PMID 12195242.

9. 9

   Ivko OM, Linkova NS, Ilina AR, Sharova AA, Ryzhak GA. [AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging.] Adv Gerontol. 2020;33(3):429-435. Published in Russian. English translation: AEDG Peptide Regulation of the Expression of Human Circadian Rhythm Genes upon Accelerated Aging of the Pineal Gland. Adv Gerontol. 2021;11(1):53-58, doi:10.1134/s2079057021010380. Russian original doi:10.34922/ae.2020.33.3.002. PMID 33280326.

10. 10

    Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. Tested Epithalamin and Thymalin, not the tetrapeptide. This journal issued no DOI for the article. PMID 14523363.

11. 11

    Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006;142(3):356-359. Tested the pineal extract, not the tetrapeptide. doi:10.1007/s10517-006-0365-z. PMID 17426848.

12. 12

    Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366-369. The published title says pituitary gland while the abstract describes the pineal preparation epithalamin; the discrepancy is the publisher's and appears identically in PubMed and Crossref. Tested the extract, not the tetrapeptide. doi:10.1007/s10517-011-1332-x. PMID 22451889.

13. 13

    Korkushko OV, Khavinson VKh, Shatilo VB, Magdich LV. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people. Bull Exp Biol Med. 2004;137(4):389-391. Tested the extract, not the tetrapeptide. doi:10.1023/B:BEBM.0000035139.31138.bf. PMID 15452611.

14. 14

    Gatta M, Dovizio M, Milillo C, Ruggieri AG, Sallese M, Antonucci I, Trofimov A, Khavinson V, Trofimova S, Bruno A, Ballerini P. The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem Cell Rev Rep. 2025;21(6):1822-1834. "G. d'Annunzio" University of Chieti-Pescara with three co-authors at the Saint Petersburg Institute of Bioregulation and Gerontology, so not an independent group. Human retinal pigment epithelial cell line, not patients. doi:10.1007/s12015-025-10911-x. PMID 40493162.

15. 15

    Ullah S, Haider Z, Perera CD, Lee SH, Idrees M, Park S, Kong IK. Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development. Life Sci. 2025;362:123381. Cattle oocytes and embryos, an animal study. doi:10.1016/j.lfs.2025.123381. PMID 39788414.

16. 16

    National Center for Biotechnology Information. PubChem Compound Summary for CID 219042, Epitalon. Molecular formula C14H22N4O9, molecular weight 390.35, CAS 307297-39-8, unique ingredient identifier O65P17785G. Synonym list of 39 entries retrieved 4 August 2026 and found to include Epithalon, Epithalone, Epithalamin and Epithalamine. pubchem.ncbi.nlm.nih.gov, CID 219042.

Related pages

Around this page: five pages on the questions this compound raises about a vial, a certificate and a number.

• What a purity figure does not establish: why a high percentage settles nothing about which substance was measured.
• How to read a COA: where identity, purity and content sit on a certificate, and what a missing impurity section means.
• What a lyophilized peptide is: the drying process behind the white powder, and what it sets and does not set.
• Routes in the trials: what changes when a study uses one route and a product uses another.
• Micrograms against milligrams: the unit slip that makes two label strengths look a thousandfold apart.

The rest of this run: the compound files still to come go out through The Decadewise briefing before they land on the site.